"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The New England Journal of Medicine, 2023
It is also explored for its potential role in supporting growth hormone activity and reducing oxidative stress in neural tissue
Semaglutide, a drug developed for diabetes that was approved for weight loss by the FDA in 2021, has dramatically risen in popularity over the last year
If you dont have insurance or have limited coverage and have type 2 diabetes, you might be able to get Victoza for free through the Novo Nordisk patient assistance program if you meet certain income and insurance criteria